About our Innovation Prize
Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.
Search
Helping pets after a natural disaster in the Carolinas
Helping pets after a natural disaster in the Carolinas
Our Innovation Prize | Partnering
Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.
U.S. FDA grants Breakthrough Therapy designation for MASH
Boehringer Ingelheim receives U.S. FDA Breakthrough Therapy designation for people living with MASH and liver fibrosis
Interview with Norbert Kraut: How cancer drives us forward
Norbert Kraut, our Global Head of Cancer Research at Boehringer Ingelheim, shares our approach to advancing cancer research and exploring new technologies
Worldwide Partnering Contacts
Worldwide Partnering Contacts
Human Health Partnering
Human Health Partnering
From garage start-up to global pharma: combining strengths to advance regenerative medicine
Article describing how a strategic partnership between Global Stem Cell and Boehringer Ingelheim Animal Health has played a key role in helping the companies accelerate breakthroughs in regenerative medicine.
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Focus on Alliance Management
Focus on Alliance Management
Our Respiratory Partnering Interests
Our Respiratory Partnering Interests
Our Immunology Partnering Interests
Our Immunology Partnering Interests
Partnering Interests in CardioMetabolic Diseases
Partnering Interests in CardioMetabolic Diseases
Our Technology Partnering Interests
Our Technology Partnering Interests
Your Guide to Partnering with Us
Your Guide to Partnering with Us
Meet our scientist
Colleagues explain why they chose Boehringer Ingelheim
Corporate Profile
Corporate Profile
Digital solutions save lives
Digital solutions save lives
Our Retinal Health Partnering Interests
Our Retinal Health Partnering Interests
Our Biotherapeutic Technology Partnering Interests
Our Biotherapeutic Technology Partnering Interests
Our Research Beyond Borders Partnering Interests
Our Research Beyond Borders Partnering Interests
Our Central Nervous System Partnering Interests
Our Central Nervous System Partnering Interests
Protecting Humans & Animals | COVID-19 | Boehringer Ingelheim US
Read more on Boehringer Ingelheim's commitment to protecting both humans and animals during the COVID-19 pandemic.
First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US
Boehringer Ingelheim and Eli Lilly and Company today announced that the EMPEROR HF (heart failure) clinical trial program was initiated.
Sustainability Matters: Carbon Neutral | Boehringer Ingelheim US
Find out more on how Boehringer Ingelheim are going carbon neutral at our manufacturing plant in Gainesville, Georgia, embracing sustainability.